Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-11-14FDA Approved: BUSPIRONE HYDROCHLORIDE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved buspirone hydrochloride from Unichem Pharmaceuticals (USA), Inc. under an Original Application for the treatment of generalized…
-
FDA approval · 2019-10-31FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Chartwell RX, LLC)
FDA approved Venlafaxine hydrochloride (extended-release) from Chartwell RX, LLC under an Original Application (ANDA).
-
FDA approval · 2019-09-11FDA Approved: PAROXETINE HYDROCHLORIDE — Supplemental Application (Apotex Corp)
FDA supplemental approval granted for Apotex Corp's paroxetine hydrochloride product, approving a generic formulation under NDA 020936.
-
FDA approval · 2019-08-29FDA Approved: VENLAFAXINE — Original Application (Modavar Pharmaceuticals LLC)
FDA approved a generic venlafaxine product from Modavar Pharmaceuticals LLC via an Original Abbreviated New Drug Application (ANDA). The gen…
-
CLINICAL_TRIALS research · 2019-08-28Clinical Trial Update: Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders [NA]
A completed clinical trial examining transdiagnostic psychotherapy for veterans with mood and anxiety disorders, with results posted in 2019…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder [Phase 3]
Phase 3 fixed-dose study investigating PD 0332334 with paroxetine for generalized anxiety disorder was terminated.
-
FDA approval · 2019-08-16FDA Approved: DULOXETINE HYDROCHLORIDE — Original Application (Yaopharma Co., Ltd.)
FDA approved the original application for duloxetine hydrochloride from Yaopharma Co., Ltd., granting approval for the generic product to be…
-
CLINICAL_TRIALS trial_result · 2019-08-15Clinical Trial Update: Treatment Study for Rural Latino Youth With Anxiety [Phase 1, Phase 2]
Clinical trial update for a treatment study in rural Latino youth with anxiety, spanning Phase 1 and Phase 2, and completed.
-
CLINICAL_TRIALS trial_result · 2019-07-25Clinical Trial Update: Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder [Phase 4]
Phase 4 clinical trial update evaluating functional MRI-based treatment validation for Generalized Anxiety Disorder has completed with resul…
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (Cipla USA, Inc.)
FDA approves Cipla USA, Inc.'s original application for pregabalin, granting a generic version of the drug for its established indications.
-
FDA approval · 2019-07-19FDA Approved: PREGABALIN — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' generic pregabalin under ANDA207623 (original application), providing a generic version of pregabalin.
-
CLINICAL_TRIALS trial_result · 2019-06-18Clinical Trial Update: Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers [Phase 3]
Phase 3 trial evaluating computerized cognitive behavioral therapy for childhood anxiety conducted in community health centers; results comp…
-
CLINICAL_TRIALS trial_result · 2019-06-14Clinical Trial Update: Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety [NA]
Completed clinical trial evaluating exposure-focused family-based CBT for youth with autism spectrum disorders and comorbid anxiety; results…
-
FDA approval · 2019-05-22FDA Approved: DULOXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approves a supplemental application for a generic duloxetine from Zydus Lifesciences Limited, authorizing marketing of the product.
-
CLINICAL_TRIALS trial_result · 2019-05-10Clinical Trial Update: Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder [Phase 3]
Phase 3 trial evaluating memantine for obsessive-compulsive disorder and generalized anxiety disorder has completed with results posted in 2…
-
FDA approval · 2019-04-17FDA Approved: DULOXETINE — Original Application (Qingdao BAHEAL Pharmaceutical Co., Ltd.)
FDA approved a generic version of duloxetine from Qingdao BAHEAL Pharmaceutical Co., Ltd. under an Original Application (ANDA 210599). The a…
-
FDA approval · 2019-04-16FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Radha Pharmaceuticals, Inc.)
FDA approves a supplemental application for buspirone hydrochloride from Radha Pharmaceuticals, Inc., granting regulatory approval for this …
-
FDA approval · 2019-04-16FDA Approved: BUSPIRONE HYDROCHLORIDE — Original Application (Epic Pharma, LLC)
The FDA approved an Original Application for Buspirone Hydrochloride from Epic Pharma, LLC, enabling a generic version of the anxiolytic for…
-
FDA approval · 2019-03-29FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Venlafaxine Hydrochloride from Sun Pharmaceutical Industries to support the generic product's co…
-
FDA approval · 2019-03-01FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for buspirone hydrochloride by Heritage Pharmaceuticals Inc. (d/b/a Avet Pharmaceuticals Inc.).
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Transdiagnostic iCBT for Depression and Anxiety [NA]
This clinical trial update reports on a transdiagnostic internet-based CBT intervention for depression and anxiety disorders, covering major…
-
CLINICAL_TRIALS trial_result · 2019-02-06Clinical Trial Update: Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study
Completed longitudinal study assessing the effectiveness of messaging-based therapy for depressive symptoms and anxiety disorders.
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD) [NA]
A completed clinical trial investigated the clinical, neurophysiological, and neuroendocrine effects of aerobic exercise in individuals with…
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD) [Phase 2]
Phase 2 exploratory trial evaluating SYN111 (Rufinamide) in generalized anxiety disorder has completed with results posted.
-
FDA approval · 2018-11-23FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Marlex Pharmaceuticals, Inc.)
FDA approved a generic venlafaxine hydrochloride product from Marlex Pharmaceuticals, marking the first original ANDA approval for this gene…